High-Priced Sickle Cell Gene Therapies Threaten to Exacerbate US Health Disparities and Establish New Pricing Precedents for Molecular Medicine

, , &
Journal of Law, Medicine and Ethics 50 (2):380-384 (2022)
  Copy   BIBTEX

Abstract

Gene therapies to treat sickle cell disease are in development and are expected to have high costs. The large eligible population size — by far, the largest for a gene therapy — poses daunting budget challenges and threatens to exacerbate health disparities for Black patients, who make up the vast majority of American sickle cell patients.

Categories

Keywords

Reprint years

DOI

10.1017/jme.2022.66

Links

PhilArchive



    Upload a copy of this work     Papers currently archived: 92,283

External links

Setup an account with your affiliations in order to access resources via your University's proxy server

Through your library

My notes

Similar books and articles

More Expensive, More Attractive? The Effect of Pricing on Gift Evaluation: Differences Between Giver and Receiver.Ning Liu, Yu Lou, Xinyu Wang & Shouxin Li - 2022 - Frontiers in Psychology 13.
Dying in the City of the Blues: Sickle Cell Anemia and the Politics of Race and Health.Troy Duster & Keith Wailoo - 2002 - Hastings Center Report 32 (4):46.
Medicine, Culture, and Sickle Cell Disease.Troy Duster - 2002 - Hastings Center Report 32 (4):46-47.
Prevention of Stroke in Sickle Cell Anemia.Robert J. Adams - 2014 - Journal of Law, Medicine and Ethics 42 (2):135-138.
Improving the justice‐based argument for conducting human gene editing research to cure sickle cell disease.Berman Chan - 2019 - Bioethics 34 (2):200-202.
Restoring a reputation: invoking the UNESCO Universal Declaration on Bioethics and Human Rights to bear on pharmaceutical pricing.Daniel J. Hurst - 2017 - Medicine, Health Care and Philosophy 20 (1):105-117.
Treating Pain in Sickle Cell Disease with Opioids: Clinical Advances, Ethical Pitfalls.Wally R. Smith - 2014 - Journal of Law, Medicine and Ethics 42 (2):139-146.
Case Study: Pain and Sickle Cell Anemia.B. A. Rich - 2001 - Hastings Center Report 31 (3):29.
Racial mixture, blood and nation in medical publications on sickle cell disease in 1950s Brazil.Juliana Manzoni Cavalcanti - 2019 - History and Philosophy of the Life Sciences 41 (4):1-23.
Racial mixture, blood and nation in medical publications on sickle cell disease in 1950s Brazil.Juliana Manzoni Cavalcanti - 2019 - History and Philosophy of the Life Sciences 41 (4):51.
Consulting communities on feedback of genetic findings in international health research: sharing sickle cell disease and carrier information in coastal Kenya. [REVIEW]Vicki Marsh, Francis Kombe, Raymond Fitzpatrick, Thomas N. Williams, Michael Parker & Sassy Molyneux - 2013 - BMC Medical Ethics 14 (1):41.
“I’m in Pain; Why Don’t You Believe Me?” Pain Management in Sickle Cell Disease.Glenn Ellis - 2021 - American Journal of Bioethics 21 (1):75-77.
Changing the Shape of Sickle Cell Disease Treatment: A Hermeneutic Study of a Case that Changed a Family and a Medical Practice.Nancy J. Moules, Catherine M. Laing & Gregory Guilcher - 2017 - Journal of Applied Hermeneutics 2017 (1).
Estimation of C-Reactive Protein, Immunoglobulin’s and Complements in SCD Patients.Maha Khalaf Al-Mishry, Nadhim K. Mahdi & Sadeq K. Ali AlSalait - 2018 - International Journal of Academic Health and Medical Research (IJAHMR) 2 (6):1-4.
Genetic Marker of Segregation: Sickle Cell Anemia, Thalassemia, and Racial Ideology in American Medical Writing 1920-1950.Keith Wailoo - 1996 - History and Philosophy of the Life Sciences 18 (3):305 - 320.

Analytics

Added to PP
2022-07-29

Downloads
16 (#911,065)

6 months
5 (#648,432)

Historical graph of downloads
How can I increase my downloads?

Citations of this work

No citations found.

Add more citations

References found in this work

No references found.

Add more references